rss
Br J Ophthalmol 2003;87:84-89 doi:10.1136/bjo.87.1.84
  • Original Article
    • Clinical science

Photodynamic therapy using verteporfin in circumscribed choroidal haemangioma

  1. B Jurklies1,
  2. G Anastassiou1,
  3. S Ortmans1,
  4. A Schüler1,
  5. H Schilling1,
  6. U Schmidt-Erfurth2,
  7. N Bornfeld1
  1. 1Department of Ophthalmology, Univ-Hospital Essen, Germany
  2. 2Department of Ophthalmology, Univ-Hospital Lübeck, Germany
  1. Correspondence to: Bernhard Jurklies, MD, Department of Ophthalmology, Universitätsklinikum Essen, Hufelandstrasse 55, D-45122 Essen, Germany; bernhard.jurklies{at}uni-essen.de
  • Accepted 5 August 2002

Abstract

Aim: To investigate the safety and efficacy of photodynamic therapy with verteporfin in patients with choroidal haemangioma.

Methods: A non-randomised, prospective clinical investigation of 19 patients with symptomatic circumscribed choroidal haemangioma was performed. Unsuccessful pretreatment (external beam irradiation, laser photocoagulation) was performed in four patients. Patients were included when (1) subretinal exudation involving the fovea, (2) a decrease in visual function, and (3) additional symptoms (for example, metamorphopsia) were present. Photodynamic therapy (PDT) was performed with verteporfin at a concentration of 6 mg/m2 body surface area and a light dose of 100 J/cm2 at 692 nm.

Results: The mean follow up time was 10.6 months (2–24 months). The mean number of treatment sessions was 2.15 (range 1–5). Visual acuity improved by at least one line in 73.3%, by at least two lines in 42.1%, was stable in 21.1%, and decreased by one line in 5.2% of the patients. Exudation was completely resolved in 94.8% of the cases. Regression of tumour height was documented in all 19 tumours. Patients receiving any pretreatment before PDT, a visual acuity of 0.1 and less, a history of more than 30 months, and no significant response after the first PDT session, did not show any significant improvement. Cox regression analysis revealed that the number of PDT treatment sessions was inversely associated with the improvement in visual acuity of at least two lines. No recurrences and no local or systemic side effects were observed during the follow up time.

Conclusion: PDT using verteporfin is a safe and effective therapy for the treatment of symptomatic choroidal haemangioma even in tumours located beneath the fovea.

Footnotes

    Register for free content


    Free sample
    This recent issue is free to all users to allow everyone the opportunity to see the full scope and typical content of BJO.
    View free sample issue >>

    Free archive
    The full back archive is now available for BJO. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006, back to volume 1 issue 1.
    Register to access the free archive >>

    Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.